What we know about India's new Covid vaccinations from Johnson & Johnson

[Andrew Reeve]

 

The single-dose vaccine from Johnson & Johnson has been licensed for emergency use in India. The vaccine, which has an efficacy rate of 85 percent, will be offered in India through a supply deal with Biological E, a local vaccine manufacturer.

When the vaccine will be available for use within India is still unknown; Johnson & Johnson claimed it was too early to specify a delivery date. More than 500 million doses of three licensed vaccinations - Covishield, Covaxin, and Russia's Sputnik V - have been administered in India thus far.

The vaccine from Johnson & Johnson is the second foreign vaccination to be approved for emergency use in India. This is due to a new policy that exempts manufacturers from doing local clinical trials, if the vaccine has previously been licensed by the WHO or regulators in the United States, the European Union, the United Kingdom, and Japan.

 

In June, the federal government awarded Cipla, an Indian pharmaceutical company, permission to import the Moderna vaccine, which has a nearly 95% efficacy rate. However, vaccinations have not been delivered because Moderna is in a legal battle with India's federal government. Moderna seeks legal protection against claims stemming from the use of the vaccines (which no vaccine maker in India currently possesses), and India has so far refused.

Only the United States has recorded more than 35 million Covid instances, with India reporting over 32 million. The daily case count has dropped dramatically from 400,000 at the peak of the second wave, but it currently hovers around 30,000 to 40,000. A third wave of Covid-19, according to scientists, is unavoidable. The country is also ranked third in the world with over 400,000 deaths, trailing only the United States and Brazil.

 

The government hopes to vaccinate all Indians by the end of the year, but the effort has been hampered by a poor vaccination efforts, a lack of vaccine doses, and vaccine skepticism. The government is now speeding up vaccination manufacturing and procurement to make up for lost time.

 

It plans to use a locally produced version of the Novavax vaccine, which will be manufactured by the Serum Institute of India (SII). According to the business, the vaccine was more than 90% effective in a late-stage clinical trial in the United States. The government has also placed an order with Biological E in India for 300 million doses of another vaccine.

Source:  BBC

 

 

 

 

[gummy]

If this vaccine, which appears from the article to be licensed from several major nations, is a one shot vaccine suitable for the Delta variant, then why is anybody/nation now ordering a two shot vaccine. Appreciate that the 2 shot was until recently all that was available but logically wouldn't a one shot bring a much more rapid coverage to the population, or are there production issues effecting its manufacture ? Interesting to hear peoples feedback, factual if possible rather then a ramble on whether a vaccine is good or bad.

[Benroon]

Isn't it a worry that Moderna (who depending on who you talk to appear to have gained the position of the holy grail of vaccines) are fighting in court to not be held responsible for its own vaccines ?!

[9S_]

1 hour ago, Benroon said:

Isn't it a worry that Moderna (who depending on who you talk to appear to have gained the position of the holy grail of vaccines) are fighting in court to not be held responsible for its own vaccines ?!

Trump waived all liability. Can’t sue them if your loved one dies from sped up trial vaccines

[Meechai]

Just my 2cents but I always said J&J was to my mind the best likely candidate

Being a viral vector vaccine (Vector-modified common cold virus) & not the newer mRNA type

 

To this day I cannot really understand why  the mass test of mRNA now during an emergency

The viral vector style vacs that we have always used is made quickly & we know they do work & have worked in the past

But as usual Im sure we are not privy to all info related to this decision to make mRNA the poster child vac for this virus

 

The Novavax vaccine (Recombinant protein/adjuvants) does also show promise with zero side effects

 

Edited August 10, 2021 by Meechai

[FlipFlopArmy]

I also prefer the proven AdVac Technology Janssen is using with a human adenovirus as vector. 
 

If a “booster “ shot is ever needed I would prefer the nanoparicle protein based vaccaine from NoVaVax.